Jiangsu Hengrui Pharmaceuticals (01276): HRS-5635 injection is included in the list of breakthrough therapeutic varieties for public notification.

Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, its subsidiary, Fujian Shengdi Medicine Co., Ltd., has had its HRS-5635 injection included in the National Medical Products Administration's list of proposed breakthrough therapy products for public notice, with a 7-day public notice period. HRS-5635 injection is a new generation of liver-targeting siRNA drug developed independently by the company for HBV. The results of Phase II clinical trials of its monotherapy for chronic hepatitis B show that HRS-5635 has the potential to improve the functional cure of chronic hepatitis B and also has good safety characteristics.